Follow us: @csjmagazine
Sponsored by
News
Next scholars of the Green Healthcare Leadership Programme announced
The Green Healthcare Leadership Programme, co-created by The Florence Nightingale Foundation (FNF) and Nuffield Health, and supported by NHS England, has awarded its second round of leadership scholarships. The scholarships were awarded to Kate Stables, Nuffield Health Plymouth Hospital, and Suzy Moody, University Hospital Southampton NHS Foundation Trust, who impressed the judges with their sustainable healthcare projects at the Celebration Event in London on Tuesday 26 March. The programme, now in its second year,
celebrated the achievements of 44 nurses, midwives and allied health professions (AHPs) from the independent sector and nurses and midwives from the NHS in England, who all completed the challenge of implementing quality improvement projects to support environmental sustainability in their workplaces. These projects include carbon- reduction and waste management initiatives that have resulted in greater use of reusables, reduction of clinical waste, and initiatives that de-carbonise patient pathways. “I am delighted that both Kate and Suzy will be joining the Florence Nightingale Foundation Scholarship Programme,” said Gemma Stacey, Deputy Chief Executive Officer of the Florence Nightingale Foundation. “In a short space of time, their projects have
both made a real difference, both in reducing waste but also embedding a sustainable healthcare
culture among the wider hospital team. I’m looking forward to seeing their progress as they develop as scholars, following an in-depth personal development plan to enhance their leadership skills. All the nurses, midwives and allied health professionals completing the programme have achieved so much with their projects and there will be a potential ripple effect across the nursing profession,” added Gemma. Ben Davies, Organisational Development
Director at Nuffield Health, commented: “Both Kate and Suzy’s projects and work throughout the programme show that nurses, midwives and allied health professionals have a key part to play in cultivating clinical excellence through sustainable service improvements. “There were fantastic results from many of the
other participants and it shows that nurses and allied health professionals have a key part to play in cultivating clinical excellence through sustainable service improvements. That’s why we created the Green Healthcare Leadership Programme with the
Florence Nightingale Foundation. “This programme will support nurses and midwives to transform the way we deliver healthcare to ensure that we can, together, reach Net Zero targets and, in doing so, give humanity a fighting chance at curbing the worse impacts of climate change.” In the first year of the Green Healthcare Leadership Programme (which started in October 2022), 18 nurses from across the independent sector completed the programme. Rachael Brown, Infection Prevention Nurse at Nuffield Health Warwickshire Hospital, was awarded a Florence Nightingale Foundation scholarship for her sustainable healthcare project that reduces the use of couch covers at Nuffield Health Warwickshire Hospital. The second year of the programme started on
17 October 2023 and nurses and midwives working in the NHS in England (bands 5-7) took part (in addition to nurses and allied health professionals from the independent sector) with 44 completing the programme. Professor Charlotte McArdle, Deputy Chief Nursing Officer for England, said: “It is great to see how Suzy and Kate’s work, and the work of other participants in the FNF Green Leadership Programme, has had a positive impact and I hope all the nurses and midwives who have taken part feel empowered to continue leading and implementing changes in their workplace, to deliver high quality care that is more cost and carbon efficient.”
NHS expands ‘one-hour’ liver testing to help detect Hep C Since the elimination programme drive began in
Thousands of people unknowingly living with hepatitis C are to be identified, diagnosed and cured thanks to major NHS investment in rapid testing technology and an extension of a ground- breaking medicines deal. New liver scanning and portable testing units will be deployed in a range of communities where patients are at high risk of contracting the infection. This includes on community clinical outreach vans, at drug and alcohol support services, or at special testing events in some GP practices as part of the final phase of the dedicated hepatitis C Elimination Programme, which could see England become the first country in the world to eliminate the virus as a public health threat. Once found by targeted outreach, hepatitis C patients can be treated on the NHS with antiviral medicines – all thanks to a two-year extension to a pioneering deal with three pharmaceutical companies, to supply the latest antiviral drugs.
2015, around 84,000 people have been treated for hepatitis C and it is hoped the virus can be stamped out as a public health concern in England, years ahead of the World Health Organization’s 2030 ambition.
NHS national medical director, Professor Sir
Stephen Powis, said: “This investment ensures the NHS will continue to save thousands of lives and set the international standard in the drive to eliminate hepatitis C by 2030 and while tackling a significant health inequality. “New portable testing devices, and an extension
of our landmark commercial deal, is helping us reach those most at risk, as we begin our final push to wipe out the virus and find and cure any remaining cases.” NHS England is investing £4.2 million to buy
25 FibroScan machines, which will be deployed in communities and care settings and facilities
where there are potential hepatitis C patients. The scanners test for liver damage and provide immediate results, referring people to onward care if needed and helping to diagnose liver disease and liver cancer at an earlier, more treatable stage. Thirty-four Cepheid GeneXpert portable
testing units will also be procured and expanded to community settings, including GP clinics and prisons, to allow the elimination programme’s teams to test people experiencing homelessness, or drug users who may struggle to meet appointments. The kit can detect whether people are infected with the hepatitis C virus in less than 60 minutes.
Complementing this, the two-year extension
of the deal originally struck in 2019 will see the NHS continuing to work together with drug firms Gilead Sciences, Merck Sharp and Dohme (MSD) and AbbVie to ensure patients can access the latest antiviral treatments.
May 2024 I
www.clinicalservicesjournal.com 9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
